Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 240,000 Shares

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 240,000 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the purchase, the insider now directly owns 2,884,121 shares in the company, valued at $14,420,605. The trade was a 9.08 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri purchased 17,000 shares of Nuvectis Pharma stock. The shares were purchased at an average cost of $4.70 per share, for a total transaction of $79,900.00.

Nuvectis Pharma Price Performance

Nuvectis Pharma stock opened at $6.29 on Wednesday. Nuvectis Pharma, Inc. has a 12-month low of $4.44 and a 12-month high of $12.10. The stock has a market capitalization of $121.52 million, a P/E ratio of -5.42 and a beta of 0.22. The firm’s 50-day moving average is $5.63 and its two-hundred day moving average is $6.34.

Institutional Investors Weigh In On Nuvectis Pharma

Several hedge funds have recently modified their holdings of NVCT. Nations Financial Group Inc. IA ADV purchased a new position in shares of Nuvectis Pharma during the 3rd quarter worth about $63,000. Oppenheimer & Co. Inc. purchased a new position in shares of Nuvectis Pharma during the 4th quarter worth about $135,000. GSA Capital Partners LLP lifted its holdings in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after acquiring an additional 1,790 shares during the period. Forbes J M & Co. LLP lifted its holdings in shares of Nuvectis Pharma by 21.9% during the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock worth $319,000 after acquiring an additional 10,599 shares during the period. Finally, Iridian Asset Management LLC CT purchased a new position in shares of Nuvectis Pharma during the 3rd quarter worth about $348,000. 96.77% of the stock is owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.